Sign In
Buy CFRX
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
Why Is ContraFect (CFRX) Stock Up 23% Today?
08:19am, Monday, 16'th Oct 2023
ContraFect (NASDAQ: CFRX ) stock is rising higher on Monday as investors react to an update from the Food and Drug Administration (FDA). The FDA has informed ContraFect that it's good to move forward
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
07:30am, Monday, 16'th Oct 2023
CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens all
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
08:30am, Tuesday, 19'th Sep 2023
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
07:30am, Monday, 18'th Sep 2023
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
08:00am, Monday, 28'th Aug 2023
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
08:30am, Monday, 14'th Aug 2023
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i
YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i
Discover the Top Penny Stock Technical Indicators By Effectiveness
06:00am, Friday, 28'th Apr 2023
Use these technical indicators to profit with penny stocks The post Discover the Top Penny Stock Technical Indicators By Effectiveness appeared first on Penny Stocks to Buy, Picks, News and Informatio
Why Is ContraFect (CFRX) Stock Down 14% Today?
09:05am, Tuesday, 18'th Apr 2023
ContraFect (NASDAQ: CFRX ) stock is dropping on Tuesday after the company revealed a notice from the Nasdaq Exchange. That notice has to do with the continued listing of CFRX stock on the exchange.
The Future of Buying Penny Stocks: Trends for 2023
07:00am, Tuesday, 18'th Apr 2023
Use these tips to invest in penny stocks right now The post The Future of Buying Penny Stocks: Trends for 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stock Investing for Passive Income: Opportunities and Risks
06:00am, Tuesday, 28'th Feb 2023
Use these tips for making passive income with penny stocks The post Penny Stock Investing for Passive Income: Opportunities and Risks appeared first on Penny Stocks to Buy, Picks, News and Information
3 Short Squeeze Penny Stocks To Watch After CFRX Stock Explodes
10:44am, Monday, 27'th Feb 2023
Penny stocks to watch with high short interest this week. The post 3 Short Squeeze Penny Stocks To Watch After CFRX Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information |
Why Is ContraFect (CFRX) Stock Up 20% Today?
08:27am, Tuesday, 31'st Jan 2023
ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. ContraFect last updated investors on Friday about its
Why Is ContraFect (CFRX) Stock Down 23% Today?
08:38am, Friday, 27'th Jan 2023
ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market. ContraFect notes in a filing with the SEC that the
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
09:21pm, Monday, 24'th Oct 2022
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
